Orrick represented Kineta on the deal. Kineta, Inc., a clinical-stage biotechnology company focused on developing novel immunotherapies in oncology that address cancer immune resistance, has entered...
TuHURA Biosciences’ Acquisition of Kineta
Kineta’s $3 Million Registered Direct Offering
Orrick Herrington & Sutcliffe LLP represented Kineta on the matter. Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology...